• Metadoro
  • Productos
  • Noticias y análisis

Noticias y análisis

Consulte las perspectivas de mercado compartidas por los miembros de nuestra comunidad
19.01.2023
Top 5 líderes de crecimiento en 2022: la soja

En el verano de 2022, los futuros de soja alcanzaron su punto máximo, con un aumento de precio del 35% desde principios de año. Al analizar este instrumento, se debe tener en cuenta que la soja se usa en dos direcciones a la vez: no solo es una parte importante de la industria alimentaria (incluso se usa para alimentar el ganado), sino que también se utiliza para producir biodiesel para automóviles. En ese sentido, es muy similar al maíz, cuyos futuros también están en el mercado. Los principales impulsores de los aumentos de precios son la alta inflación, que eleva el costo de producción, la falta de fertilizantes y la incertidumbre relacionada con el clima en las regiones clave donde se cultiva la soja. En 2022, se cosecharon 163 millones de toneladas de soja en América Latina (principalmente en Brasil y Argentina), más que en los Estados Unidos, China e India. Varios brokers agrícolas esperan un nuevo aumento en la inflación de los alimentos. Se necesitan cosechas récord para satisfacer la demanda actual, mientras que un mal clima y los altos precios de la energía limitan significativamente la oferta.

16.03.2023
¿Qué hará el S&P 500 después de caer a los 3400 puntos?

Los futuros sobre el índice de mercado amplio S&P 500 están resbalando cada vez más, mostrando que el intento de romper el límite superior del canal descendente a principios de febrero, aparentemente, no tuvo éxito. Y si es así, entonces es hora de considerar un plan aproximado para la caída del principal índice de referencia bursátil. En la mayoría de los casos, luego de que un instrumento financiero no logra romper un nivel importante, recibe un fuerte contraataque debido a la debilidad mostrada. Creo que en el caso de los futuros del S&P 500, esto significa un retorno lógico a la mitad del actual canal bajista en la zona de los 3400 puntos. Donde, como podemos ver, se ubica el primer nivel técnico muy fuerte. Tal caída en el índice de referencia bursátil estadounidense se correlaciona bien con la situación actual, cuando los mercados están temblando debido a la crisis bancaria en EE. UU. y Europa. Personalmente, prácticamente no tengo dudas sobre una caída a este nivel. Pero luego, las opciones demasiado polares y extremas sugieren una bifurcación en 3400 puntos.

Es posible que la situación se aclare durante la caída del mercado, pero hasta ahora lo máximo con lo que se puede contar vendiendo futuros del índice S&P 500, es su caída en el próximo mes y medio entre 12 y 14%.

21.04.2022
Tres acciones que están atrayendo la atención de los alcistas: Procter & Gamble

El informe financiero del famoso fabricante mundial de productos del segmento de consumo del primer trimestre de 2022 mostró todos los signos de un crecimiento estable de los ingresos, que alcanzaron los 19,38 mil millones de dólares, un 3,5% más de lo que esperaban los analistas de Wall Street, y también un 7% más del período correspondiente en 2021. Pero en comparación con la temporada prenavideña de fin de año, las cifras son, por supuesto, menores. Contrariamente a las afirmaciones de que las presiones de los precios de compra están perjudicando las ganancias de los productores, las ganancias por acción (EPS) aumentaron 7 centavos durante año a 1,33 dólares. Los suministros de productos médicos como Oral-B y Pepto-Bismol aumentaron un 13%.

Procter & Gamble elevó su pronóstico de ventas anual y confirmó que la demanda de productos de higiene y cuidado de la salud sigue siendo estable a pesar del aumento de los precios. "Orgánicamente, el crecimiento de los ingresos será del 6% al 7%", dijo la compañía, que está por encima del pronóstico de consenso de los analistas del 5,5%. Las acciones de Procter & Gamble subieron un 3% inmediatamente después de los datos trimestrales, deteniéndose en 88 centavos por debajo de su máximo de enero. Está claro que el precio no se mantendrá en los niveles actuales después de subir un 17,5% desde enero de 2021. Andre Schulten, vicepresidente de asuntos financieros de la compañía, dijo que espera una disminución de BPA de 1 centavo en el tercer trimestre debido al conflicto militar en Ucrania. En el cuarto trimestre, esta cifra puede disminuir en otros 4 centavos. El comentario sigue a la decisión de la compañía de dejar de invertir en Rusia y "reducir sustancialmente" su línea de productos, centrándose en productos de higiene, productos médicos y de cuidado personal. Rusia y Ucrania representan alrededor del 1,5% de todas las ventas de la empresa.

El negocio basado en la producción de productos de consumo diario suele ser más resistente durante una tormenta inflacionaria. Produce productos simples y necesarios que las personas han estado usando durante años y están acostumbrados a ellos. Es poco probable que las amas de casa renuncien a Pampers, Tampax o Always, y es poco probable que sus esposos que usan maquinillas para afeitar Gillette, estén listos para cambiar a otras marcas, especialmente cuando sus precios también están aumentando.

26.01.2023
Top 5 perdedores de 2022: Consumo discrecional

En 2022, todo el sector de consumo discrecional, que incluye empresas que producen bienes no esenciales: automóviles, ropa, artículos de lujo, hoteles, restaurantes, etc., fue muy afectado. Cuando llegan tiempos difíciles, la gente sigue comprando comida, pero comienza a ahorrar en otras áreas. Los temores sobre la inflación y la recesión inminente provocaron el colapso del ETF XLY en casi 40% a finales de año. Sin embargo, tales reducciones a menudo brindan excelentes oportunidades de inversión, ya que es raro ver acciones de compañías icónicas como Nike, Toyota y Home Depot tan lejos de sus valores máximos. Los informes macroeconómicos recientes apuntan a que quizás los temores de una disminución en la demanda de los consumidores son demasiado pesimistas. Las ventas minoristas en EE.UU. durante la temporada navideña fueron bastante fuertes (según Mastercard, el gasto en los Estados Unidos aumentó 7.6% interanual entre el 1 de noviembre y el 24 de diciembre), y los empleadores siguen buscando nuevo personal. Tal dinámica favorece el aumento de los salarios y la preservación de la actividad de consumo.

28.03.2023
Axie Infinity: el pionero de play-2-earn ha perdido relevancia

En 2021, el juego Axie Infinity basado en blockchain se convirtió en un verdadero descubrimiento: la cantidad de personas que querían ganar dinero criando animales y participando en batallas se disparó, gracias a lo cual el valor del token se disparó en más del 1000% en noviembre. Desde entonces, muchos proyectos han intentado repetir el éxito de Axie, pero todos han tenido el mismo final triste.

El problema de proyectos de este tipo es fundamental. Cuando un token de juego comienza a cotizar en una bolsa, su precio se vuelve extremadamente vulnerable a la afluencia de usuarios. Tan pronto como disminuye, se vuelve imposible mantener la presión de los vendedores, como resultado de lo cual las cotizaciones caigan como una piedra. Cabe recordar que con el aumento del valor de las monedas, aumenta el umbral de entrada. No todos pueden pasar mucho tiempo en un juego muy monótono, especialmente cuando la recompensa financiera se vuelve mínima. Axie también sufre de este malestar. Diversas estrategias de marketing, como mayores recompensas para los jugadores activos, no son capaces de cambiar fundamentalmente la situación. Si a finales de 2021 el número de compradores únicos de AXS era alrededor de 500 mil, en los últimos meses su número no ha superado los 20 mil. En este sentido, a los inversores se recomienda buscar nuevos proyectos que puedan dispararse durante el próximo ciclo alcista. Son los primeros usuarios los que tienen la oportunidad de ganar mucho dinero, incluso vendiendo sus tokens a especuladores lentos que realizan compras después de que sube el precio.

Walmart's Further Bullish Prospects

Walmart quarterly numbers quite predictably beat even the crowd's lofty expectations in both revenue and profit opening the way to new price peaks. During the first 5 minutes after the release, the market response was an immediate taking off and soaring by 6.6%, from $68.66 to $73.20 per share. The previous high for Walmart stock was detected at $71.33 on July 19, so that means entering into a new price area for the US largest chain of economy class hypermarkets. Even before the report, many investment houses formed their consensus opinion that Walmart was still in Overweight position, with their price targets well above $80. And now the whole situation not only looks better, but bullish prospects for the stock are also easier to understand. Walmart announced its quarterly EPS of $0.67, just a $0.03 better than the analyst estimate of $0.64, yet this number set an absolute record on a 9.2% surplus YoY, of course if the whole date series for years would be retroactively adjusted for the 1:3 stock split, which has been accomplished at the end of February. Moreover, the current achievement is shown despite its revenue record still not exceeded, pointing at smart and profitable pricing policy in a challenging environment. Walmart's revenue for the last quarter came out at $169.3 billion, which can be called weaker only when compared with $173.4 billion in the Christmas quarter. We can agree this would not be an exactly valid comparison with an all-time record for the sale-off season. Besides, its YoY growth is 4.7% in sales, with the consensus estimate for Q2 being at $168.52 billion, against $161.6 billion in Q2 2023.

The further pace of the rally in Walmart could be limited by the company's moderately shying forward guidance as it sees Q3 EPS of $0.51-$0.52 vs analyst poll consensus of $0.54 and a $2.35-$2.43 range for its annual EPS for the financial year or 2025 average analyst bets on $2.43. However, this would barely derail the upside move as Walmart investors knew from their previous experience that their favourite company's management prefers to understate expectations and later beat them. Again, Walmart's own prior forecast was "at the high end of a range of $2.23 to $2.37 per share", and so an actual raising of its profit forecasts happened. Its fiscal 2025 net sales growth is foreseen in between 3.75% and 4.75% from a prior range of 3% to 4% growth. The number of transactions, which indicates store visits, rose 3.6% in U.S. stores and online orders. The average ticket, which means how much Walmart visitors are spending per one visit, is 0.6% up YoY.

Surely, rising sales of inexpensive essentials, with an already beginning deterioration in the labour market, helps discounter chains compared to the average consumer activity in other shops. Walmart accounts for $1 of every $5 spent on groceries in the United States. But Walmart's reputation as a destination for upper-income shoppers has expanded for the last several years, because of mighty merchandise upgrades and investments in curbside pickup and delivery. This is why online sales in Walmart added 22% YoY. Anyway, Walmart's report ahead of the opening bell on August 15, being a major market bellwether of the week, also sets the positive mood for nearest days, revealing some further upside potential for the rest of the consumer segment at least.

5298
B
Inflation Data Sparked a Recovery Mood

The US S&P 500 broad market barometer continued to crawl out of the underground area when the price twice touched the levels below 5,200 points during the previous week. The crowd climbed a 5,400 wall just the day before and then edged to nearly 5,450 on today's consumer prices (CPI) data. The further growth still looks slower and erratic as the US July CPI was actually low but unsurprising. And so, this is a natural action after the sudden fright, even though recession signs seem to have receded. As expected, expert opinions began to vie with each other that it is premature to talk about the economy slipping into recession, as the process should be characterized by a persisting decline in consumption, which has not been noticed or confirmed yet. Meanwhile, inflation pressure scaled back to support optimistic scenarios for the Federal Reserve's rate cut this autumn.

The US CPI rose by 2.9%, as of the latest governmental release to slightly moderate the pace vs 3.0% one month ago, while the polls projected the number would be kept intact at 3.0%. Better than nothing, even taking into consideration that prices added another 0.2% MoM, both in the headline and underlying inflation slices, compared to falling/rising within 0.1% in mid-summer. The so-called "core" CPI also came out at 3.2% in the twelve months to July, which was below average forecasts of 3.3%. The PPI (producer price index) release on Tuesday showed the "core" inflation was cooling as the PPI, excluding most unstable food and energy components, was flat on the month and narrowed the annual indications to 2.4% from a widely estimated range of 2.5% to 2.7%. This means a rate reduction cycle is just around the corner, which may contribute to the recovery mood.

Immediate price increases need not necessarily to take place on Wall Street, yet step-by-step climbing on the path to the top with buying dips on the tech segment bellwethers, and more selectively on broader markets as well, are most likely. More or less risky developments, including a retest of 5,250 to 5,300 on the S&P 500, cannot be excluded. However, appearing at new market lows of August in the AI-related or most consumer stocks is not highly plausible anymore.

4182
B
Starbucks Is Unsinkable

I told you before that I strongly believe in Starbucks' ability to get out of whatever jam it was temporarily in. Today life proved they could keep the coffee dry enough to resurface at any moment.

This week is probably all about inflation data, with US CPI is scheduled for Wednesday, and retailers, starting with Home Depot's quarterly report on Tuesday (was not very bright, but not disappointing at least) and the major Walmart report on Thursday. However, Starbucks news was hosed ahead of the race with a sudden management miracle. It named now-the-former CEO of extremely successful Chipotle Mexican Grill as Starbucks' new CEO, effective since September 9. This important leadership change immediately pushed Starbucks share price more than 20% up, which may be too much for the particular moment, but looks promising for improving the coffee chain's sales in North America and China. Therefore, I personally feel that any price retracement to the levels below $90 could become a golden Buy opportunity. IMHO, even $85 is possible as a short-time episode, but sliding to $75 again would be nearly unbelievable.

Brian Niccol is credited with the splendid thriving of his company since he took the helm in 2018. He doubled Chipotle's revenue and provided its stock price ride to the moon, adding somewhat 700% or 800%, not only because people love burritos so much but also due to his focus on brand culture, menu innovation as well as digital transformation of Chipotle's service. I bet you at least a thousand bucks that Starbucks would become the same kind of riding-to-the-moon-and-stars company very soon, as Niccol is a the Manager to recover the brand's global influence. His leadership expanded from P&G and Taco Bell to Pizza Hut, and he also served on the board of directors for Walmart and even held positions on the boards of Harley-Davidson. For me, it's a kind of miracle-making coach, like Guus Hiddink was in football, so that he pushed even Australians, South Koreans and even slow Russians to play the game. Howard Schultz, the legendary Starbucks founder and chairman emeritus, also expressed his admiration for Niccol's "impact on retail excellence", particularly his ability to "lead a culture and values-driven enterprise."

Well, let's just hold and see. Hope, with a view to repeating July 2021 with its above $120 records, for the beginning.

5598
The Best-Looking Biotech Stock

After three weeks of a severe technical retracement from an all-time high at $966 on July 15 to fresh dips below $750 in early August, Eli Lilly revealed itself once again as the most attractive company for mass. The company's new and popular weight loss treatment Mounjaro statistically results in a more remarkable growing thin effect than rivals' obesity drugs, in a real-world comparison across other benchmarks, including Novo Nordisk's obesity drug named Wegovy or Ozempic, which are actually two different brand names for the same injectable drug, semaglutide, AMA Internal Medicine journal reported about a month ago. Patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking the second place drug, researchers found after analysing weight loss trajectories in 9,193 patients. Mounjaro sales reached $3.1 billion, with best growth pace in the UK, UAE and Saudi Arabia markets, and now Eli Lilly additionally reports robust, and better than expected, financial growth.

Its quarterly EPS (equity per share) just came out at $3.92 on $11.3 billion of total sales vs nearly $2.75 per share on about $10 billion in consensus estimates, and also against $2.54 per share on $8.77 billion in the previously record quarter, meaning a 42.5% QoQ and a 85.2% YoY surplus in EPS. What a wonderful margin performance in a very challenging environment! Eli Lilly's CEOs revised their annual revenue outlook upwards to forecast it between $45.4 billion and $46.6 billion for 2024, following a 36% increase in revenue YoY so far and "with operating margins in the mid- to high-30s range". Revenue in Europe added 20% in constant currency, 15% in Japan and 61% in the "rest of the world" (outside the US. and the EU).

Eli Lilly's share price quickly soared to $875 to $905 resistance area before the weekend, while a rather sceptical Deutsche Bank immediately upgraded the stock from Hold to Buy with a 15% of additional upside potential to $1,025 at least and BMO Capital Markets provided its rosy path assessment with a new price target at $1,101 from $1,001. Even average expert poll projections are shifted to a $4.28 of EPS at nearly $12 billion of sales for Q3. And so, we do agree with a more optimistic outlook, feeling that the most prominent manufacturing expansion in the biopharma industry since the pandemic time should be given not only a praise but also monetary rewards. Its current supply capacity is 1.5 times above the level which was measured only 1.5 ago.

The company continues to invest heavily in its manufacturing and expansion, with over $18 billion committed to facilities and announced plans to put an extra $5.3 billion in its manufacturing sites in Indiana. It is ready to acquire Morphic Therapeutic as well to better withstand chronic diseases. It achieved "the approval of Kisunla, the brand name for donanemab in the US for the treatment of Alzheimer's disease, the approval of Jaypirca in Japan for people with relapsed or refractory mantle cell lymphoma, the submission of tirzepatide in the U.S. and the EU for the treatment of moderate to severe obstructive sleep apnoea in adults with obesity and the positive top line results from the SUMMIT Phase 3 trial evaluating tirzepatide in adults with heart failure with preserved injection fraction and obesity", according to last earnings call's materials. This is an impressive list of achievements to generate both more healthy life profits. Besides, Eli Lilly raises its dividend payment for 9 consecutive years. It now equals to $1.3 per share, maybe not much compared to the stock's price growth but is also a pleasant indication of the company's self-confidence.

4666
141

Únete a nuestra comunidad

Comparta sus observaciones profesionales y aficionadas, intercambie experiencias, anticipe desarrollos

Categoría
Todo
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instrumentos
Autor
Todo
Metadoro
Colaboradores